Hepatocellular carcinoma/liver cancer

liver
Transcatheter arterial chemoembolization (TACE) combined with apatinib (TACE-apatinib) prolonged time to progression (TTP) and overall survival (OS) compared to TACE-alone for Barcelona Clinic Liver Cancer (BCLC) stage C HCC, according to a study published in BMC Cancer. This retrospective study… Read More
HCC cells
No significant difference in overall survival (OS) and liver cancer-specific survival (LCSS) was found in patients with localized hepatocellular carcinoma (HCC) treated with either cryoablation (cryo) or radiofrequency ablation (RFA), according to a study published in Anticancer Research. This… Read More
HCC cells
A new study that looked at outcomes of surgical resection after yttrium-90 (Y90) transarterial radioembolization (TARE) in patients with hepatocellular carcinoma found that TARE can serve as a safe bridge to resection. The results were published in the Journal of Vascular and Interventional… Read More
HCC cells
Tumor response can be predicted after Yttrium-90 (90Y) radioembolization in patients with hepatocellular carcinoma (HCC) by analyzing the delivered tumoral radiation dose by internal pair-production positron emission tomography (PET) dosimetry, according to a study published in the International… Read More
Alice Gillams, MB, CHB
In this video, Alice Gillams, MB, CHB, discusses the benefits of liver directed therapy. 
HCC cells
In a recent systemic review and meta-analysis, researchers found that preoperative strategies are able to effectively increase resectability rates for patients with hepatocellular carcinoma (HCC). The investigators searched PubMed, EMBASE, Cochrane and Scielo/LILACS for studies that included… Read More
liver
Patients with caudate hepatocellular carcinoma (HCC) within the Milan criteria may experience better results with radiofrequency ablation (RFA) than with transarterial chemoembolization (TACE), according to a study published in Cardiovascular and Interventional Radiology. Although HCC in the… Read More
liver
The combination of sorafenib and transarterial chemoembolization (TACE) for patients with advanced hepatocellular carcinoma (HCC) seems feasible and promising, researchers reported. Phase III trials have not shown a clinical benefit of the combined therapy, but there have been signs of promise in… Read More
HCC cells
Inhibition of cancer stem cells in hepatocellular carcinoma (HCC) may improve the efficacy of percutaneous thermal ablation, transarterial chemoembolization (TACE), and transarterial embolization (TAE), according to an abstract presented at the World Conference on Interventional Oncology. Patients… Read More
liver cancer
An analysis of 9 studies has concluded that transarterial chemoembolization (TACE) plus iodine-125 seed results in better clinical outcomes than TACE alone for patients with hepatocellular carcinoma (HCC). TACE is a recommended effective treatment for patients with advanced HCC, and recent… Read More